EU/3/01/046: Orphan designation for the treatment of graft-versus-host disease


Table of contents


Please note that this product was withdrawn from the Community Register of designated Orphan Medicinal Products in December 2008 on request of the Sponsor.

On 9 July 2001, orphan designation EU/3/01/046 was granted by the European Commission to Laboratoires LAPHAL, France, for thalidomide for the treatment of graft versus host disease.

The sponsorship was transferred to Laphal Developpement in September 2002. Laphal Developpement changed name to Pharmion Developpement in 2004 and Pharmion Developpement changed name to Pharmion France in 2007.

Key facts

Active substance
Intended use
Treatment of graft-versus-host disease
Orphan designation status
EU designation number
Date of designation
Pharmion France
6/8 Boulevard Haussmann
75009 Paris
Telephone : +33 1 42 99 97 02
Telefax : +33 1 42 99 97 01

Documents related to this orphan designation evaluation

Patients' organisations

For contact details of patients’ organisations whose activities are targeted at rare diseases, see:

  • European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.

  • Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe.

EU register of orphan medicines

The list of medicines that have received an orphan designation in the EU is available on the European Commission's website:

How useful was this page?

Add your rating